249 related articles for article (PubMed ID: 31630241)
1. Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.
Jochim A; Meindl T; Huber C; Mantel T; Zwirner S; Castrop F; Haslinger B
J Neurol; 2020 Jan; 267(1):267-275. PubMed ID: 31630241
[TBL] [Abstract][Full Text] [Related]
2. Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.
Jochim A; Meindl T; Mantel T; Zwirner S; Zech M; Castrop F; Haslinger B
J Neurol; 2019 Aug; 266(8):1879-1886. PubMed ID: 31049731
[TBL] [Abstract][Full Text] [Related]
3. The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome.
Bastola P; Chaudhary M; Agrawal JP; Shah DN
Kathmandu Univ Med J (KUMJ); 2010; 8(31):305-10. PubMed ID: 22610735
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin in Meige's syndrome: A video-based case series.
Pandey S; Sharma S
Neurol India; 2018; 66(1):71-76. PubMed ID: 29322963
[TBL] [Abstract][Full Text] [Related]
5. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of blepharospasm with botulinum toxin A: a service-based study over a 16-year follow-up in southern China.
Fang XB; Xie MS; Song ZB; Zhong ZG; Wang Y; Ou ZL; Dang C; Li L; Zhang WX
Neurol Sci; 2020 Mar; 41(3):645-652. PubMed ID: 31745757
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
8. Current status of dystonias including Meige's syndrome.
Behari M
Neurol India; 2018; 66(1):36-37. PubMed ID: 29322952
[No Abstract] [Full Text] [Related]
9. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Lolekha P; Choolam A; Kulkantrakorn K
Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
[TBL] [Abstract][Full Text] [Related]
10. Botulinum A toxin treatment for blepharospasm and Meige syndrome: report of 100 patients.
Poungvarin N; Devahastin V; Chaisevikul R; Prayoonwiwat N; Viriyavejakul A
J Med Assoc Thai; 1997 Jan; 80(1):1-8. PubMed ID: 9078810
[TBL] [Abstract][Full Text] [Related]
11. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years.
Mauriello JA; Dhillon S; Leone T; Pakeman B; Mostafavi R; Yepez MC
Br J Ophthalmol; 1996 Dec; 80(12):1073-6. PubMed ID: 9059273
[TBL] [Abstract][Full Text] [Related]
12. Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study.
Wein T; Jog M; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
Can J Neurol Sci; 2019 Nov; 46(6):742-752. PubMed ID: 31256770
[TBL] [Abstract][Full Text] [Related]
13. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin.
Van den Bergh P; Francart J; Mourin S; Kollmann P; Laterre EC
Muscle Nerve; 1995 Jul; 18(7):720-9. PubMed ID: 7783762
[TBL] [Abstract][Full Text] [Related]
14. [Meige's syndrome or segmental craniocervical dystonia: terminology, history and contemporary view].
Zalyalova ZA
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(12):133-136. PubMed ID: 26978507
[TBL] [Abstract][Full Text] [Related]
15. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
Grosset DG; Tyrrell EG; Grosset KA
J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
[TBL] [Abstract][Full Text] [Related]
16. Altered functional connectivity in blepharospasm/orofacial dystonia.
Jochim A; Li Y; Gora-Stahlberg G; Mantel T; Berndt M; Castrop F; Dresel C; Haslinger B
Brain Behav; 2018 Jan; 8(1):e00894. PubMed ID: 29568690
[TBL] [Abstract][Full Text] [Related]
17. Use of botulinum toxin in Meige's disease.
Maurri S; Brogelli S; Alfieri G; Barontini F
Riv Neurol; 1988; 58(6):245-8. PubMed ID: 3247565
[TBL] [Abstract][Full Text] [Related]
18. Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders-A retrospective tolerability and safety study.
Anderson CC; Iser CR; Hirte IL; Boddu S; Girardo ME; VanderPluym JH; Starling AJ
Headache; 2024 Jun; 64(6):663-673. PubMed ID: 38700250
[TBL] [Abstract][Full Text] [Related]
19. [Botulinum toxin A in therapy of craniocervical dystonias and hemifacial spasm].
Thill R; Költringer P; Reisecker F; Maller J; Leblhuber F
Acta Med Austriaca; 1991; 18(5):125-9. PubMed ID: 1796725
[TBL] [Abstract][Full Text] [Related]
20. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results.
Calace P; Cortese G; Piscopo R; Della Volpe G; Gagliardi V; Magli A; De Berardinis T
Eur J Ophthalmol; 2003 May; 13(4):331-6. PubMed ID: 12872788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
